Sinopharm Group (09688.HK) released its interim results, with total revenue of 216 million US dollars, a year-on-year increase of 15.35%.

The Zhixin Finance APP reported that RenDing Pharmaceuticals (09688.HK) released its mid-term performance for 2025, with the group achieving a total revenue of 216 million US dollars, an increase of 15.35% year-on-year; a net loss of 91.65 million US dollars, a decrease of 33.33% year-on-year; and a loss per share of 0.08 US dollars.